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Background
MUTYH-associated polyposis (MAP) is an autosomal
recessive disorder that is caused by germline mutations
in the base excision repair gene MUTYH. Phenotypic
expression is usually that of an attenuated polyposis syn-
drome with anywhere from 3-100+ polyps and mixed
pathology including tubular adenomas, sessile serrated
adenomas, and/or hyperplastic polyps. The use of non-
steroidal anti-inflammatory drugs (NSAIDs) has been
well established as a method of polyp chemoprevention
and suppression in familial adenomatous polypsis syn-
drome (FAP). However, while cyclooxygenase-2 expres-
sion has been confirmed in the adenomas, synchronous
adenocarcinomas, and healthy mucosa in APC-/MYH+
patients,
1 it is not well-documented if NSAIDS have any
effect on polyp formation in patients with MAP.
Case report
We report a patient who presented to our clinic with
polyposis coli in 2008 after having begun screening
colonoscopies at age 44 due to a family history of color-
ectal cancer (CRC), significant for a brother with colon
cancer at age 39 and a sister with polyps/colon cancer
at age 71. Given his personal and family history, an atte-
nuated polyposis syndrome was suspected. Genetic test-
ing for APC and MUTYH gene mutations was
performed, and he was found to carry biallelic mutations
in the MUTYH gene (G382D, Y165C). Polyp progres-
sion is well-documented in this patient after his initial
colonoscopy in 1994 revealed one small hyperplastic
polyp. A total of 7 colonoscopies were done between
1994 and 2006 during which time there were anywhere
from 1-6 adenomatous polyps removed. Throughout
this time and prior to his first colonoscopy, he utilized
scheduled NSAIDs continuously for arthritis (naproxyn
sodium followed by celecoxib). In December 2006, cele-
coxib was discontinued due to a positive stress test and
subsequent triple bypass, after which he was placed on
only daily 81mg aspirin. The next colonoscopy done
18 months later in 2008 showed multiple polyps
throughout the right colon which was a significant
change from previous scopes. He was referred to our
clinic for evaluation as noted and subsequently under-
went a total abdominal colectomy with ileorectal
anastomosis.
Discussion
While his polyp progression may be due to the natural
history of his MAP, the chronologic proximity of the
advancement of his polyposis phenotype appears more
than coincidental. Further studies utilizing NSAIDs for
chemoprevention in MAP should be considered.
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